...
首页> 外文期刊>Chemical and Pharmaceutical Bulletin >Identification of a Novel Cannabimimetic Phenylacetylindole, Cannabipiperidiethanone, as a Designer Drug in a Herbal Product and Its Affinity for Cannabinoid CB1 and CB2 Receptors
【24h】

Identification of a Novel Cannabimimetic Phenylacetylindole, Cannabipiperidiethanone, as a Designer Drug in a Herbal Product and Its Affinity for Cannabinoid CB1 and CB2 Receptors

机译:新型的拟大麻素苯基乙酰吲哚,Cannabipiperidiethanone,作为草药产品中的设计药物的鉴定及其对大麻素CB1和CB2受体的亲和力

获取原文

摘要

A new cannabimimetic phenylacetylindole (cannabipiperidiethanone, 1 ) has been found as an adulterant in a herbal product which contains two other known synthetic cannabinoids, JWH-122 and JWH-081, and which is distributed illegally in Japan. The identification was based on analyses using GC-MS, LC-MS, high-resolution MS and NMR. Accurate mass spectrum measurement showed the protonated molecular ion peak of 1 at m / z 377.2233 [M+H]+ and the molecular formula of 1 was C24H29N2O2. Both mass and NMR spectrometric data revealed that 1 was 2-(2-methoxyphenyl)-1-{1-[(1-methylpiperidin-2-yl)methyl]-1 H -indol-3-yl}ethanone. Compound 1 has a mixed structure of known cannabimimetic compounds: JWH-250 and AM-2233. Namely, the moiety of phenylacetyl indole and N -methylpiperidin-2-yl-methyl correspond to the structure of JWH-250 and AM-2233, respectively. However, no synthetic, chemical or biological information about 1 has been reported. A binding assay of compound 1 to cannabinoid receptors revealed that 1 has affinity for the CB1 and CB2 (IC50=591, 968 n M , respectively) receptors, and shows 2.3- and 9.4-fold lower affinities than those of JWH-250. This is the first report to identify cannabimimetic compound ( 1 ) as a designer drug and to show its binding affinity to cannabinoid receptors.
机译:在一种含有两种其他已知合成大麻素JWH-122和JWH-081的草药产品中,发现一种新的仿大麻苯基乙酰吲哚(大麻素哌啶酮,1)作为掺假品,并在日本非法销售。鉴定基于使用GC-MS,LC-MS,高分辨率MS和NMR的分析。精确的质谱测量显示,质子化的分子离子峰在m / z 377.2233 [M + H] + 处,分子式为C 24 H 29 N 2 O 2 。质谱和NMR光谱数据均显示1为2-(2-甲氧基苯基)-1- {1-[(1-甲基哌啶-2-基)甲基] -1H-吲哚-3-基}乙酮。化合物1具有已知的拟大麻化合物JWH-250和AM-2233的混合结构。即,苯基乙酰基吲哚和N-甲基哌啶-2-基-甲基的部分分别对应于JWH-250和AM-2233的结构。但是,没有关于1的合成,化学或生物学信息的报道。化合物1与大麻素受体的结合试验表明,化合物1对CB 1 和CB 2 具有亲和力(IC 50 = 591,968 n M受体),其亲和力比JWH-250低2.3倍和9.4倍。这是鉴定大麻模拟化合物(1)为设计药物并显示其与大麻素受体结合亲和力的第一份报告。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号